RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) Director Laurence Marton acquired 12,050 shares of the company's stock in a transaction on Tuesday, April 8th. The shares were purchased at an average cost of $0.85 per share, with a total value of $10,242.50. Following the completion of the purchase, the director now directly owns 45,684 shares of the company's stock, valued at $38,831.40. This trade represents a 35.83 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
RenovoRx Stock Performance
Shares of RNXT stock opened at $0.79 on Friday. The stock has a 50 day moving average price of $1.01 and a 200 day moving average price of $1.13. RenovoRx, Inc. has a 52-week low of $0.75 and a 52-week high of $1.69. The firm has a market capitalization of $18.98 million, a P/E ratio of -1.39 and a beta of 1.12.
RenovoRx (NASDAQ:RNXT - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.17 million. As a group, sell-side analysts forecast that RenovoRx, Inc. will post -0.4 EPS for the current year.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a "buy" rating and set a $3.00 price target on shares of RenovoRx in a report on Friday, April 4th.
View Our Latest Report on RNXT
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in RenovoRx by 61.9% in the 3rd quarter. Geode Capital Management LLC now owns 232,937 shares of the company's stock worth $247,000 after acquiring an additional 89,018 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of RenovoRx in the 4th quarter worth $49,000. Finally, Renaissance Technologies LLC bought a new position in shares of RenovoRx during the 4th quarter worth $84,000. Hedge funds and other institutional investors own 3.10% of the company's stock.
About RenovoRx
(
Get Free Report)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
